Show simple item record

dc.contributor.authorJha, Ruchira M
dc.contributor.authorRani, Anupama
dc.contributor.authorDesai, Shashvat M
dc.contributor.authorRaikwar, Sudhanshu
dc.contributor.authorMihaljevic, Sandra
dc.contributor.authorMunoz-Casabella, Amanda
dc.contributor.authorKochanek, Patrick M
dc.contributor.authorCatapano, Joshua
dc.contributor.authorWinkler, Ethan
dc.contributor.authorCiterio, Giuseppe
dc.contributor.authorHemphill, J Claude
dc.contributor.authorKimberly, W Taylor
dc.contributor.authorNarayan, Raj
dc.contributor.authorSahuquillo, Juan
dc.contributor.authorSheth, Kevin N
dc.contributor.authorSimard, J Marc
dc.date.accessioned2021-11-18T16:39:32Z
dc.date.available2021-11-18T16:39:32Z
dc.date.issued2021-11-02
dc.identifier.urihttp://hdl.handle.net/10713/17144
dc.description.abstractSulfonylurea receptor 1 (SUR1) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) protein superfamily, encoded by Abcc8, and is recognized as a key mediator of central nervous system (CNS) cellular swelling via the transient receptor potential melastatin 4 (TRPM4) channel. Discovered approximately 20 years ago, this channel is normally absent in the CNS but is transcriptionally upregulated after CNS injury. A comprehensive review on the pathophysiology and role of SUR1 in the CNS was published in 2012. Since then, the breadth and depth of understanding of the involvement of this channel in secondary injury has undergone exponential growth: SUR1-TRPM4 inhibition has been shown to decrease cerebral edema and hemorrhage progression in multiple preclinical models as well as in early clinical studies across a range of CNS diseases including ischemic stroke, traumatic brain injury, cardiac arrest, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, multiple sclerosis, encephalitis, neuromalignancies, pain, liver failure, status epilepticus, retinopathies and HIV-associated neurocognitive disorder. Given these substantial developments, combined with the timeliness of ongoing clinical trials of SUR1 inhibition, now, another decade later, we review advances pertaining to SUR1-TRPM4 pathobiology in this spectrum of CNS disease-providing an overview of the journey from patch-clamp experiments to phase III trials.en_US
dc.description.urihttps://doi.org/10.3390/ijms222111899en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofInternational Journal of Molecular Sciencesen_US
dc.subjectSUR 1en_US
dc.subjectTRPM4en_US
dc.subjectcellular swellingen_US
dc.subjectclinical trialsen_US
dc.subjectedemaen_US
dc.subjectstrokeen_US
dc.subjectsulfonylurea receptoren_US
dc.subjecttraumatic brain injuryen_US
dc.titleSulfonylurea Receptor 1 in Central Nervous System Injury: An Updated Reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/ijms222111899
dc.identifier.pmid34769328
dc.source.volume22
dc.source.issue21
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record